risk
indic
viral
load
ct
lymphocyt
percentag
lym
creactiv
protein
crp
procalcitonin
pct
lactic
acid
la
patient
propos
recent
studi
howev
predict
effect
indic
diseas
classif
prognosi
remain
larg
unknown
dynam
measur
report
indic
case
patient
includ
moderatecur
moder
cure
severecur
sever
cure
critic
ill
die
data
show
crp
pct
lym
lactic
acid
viral
load
could
predict
prognosi
guid
classif
patient
differ
degre
crp
lym
effect
three
factor
predict
prognosi
diseas
classif
crp
lym
sensit
identifi
type
critic
ill
sever
moder
notabl
among
investig
factor
lym
one
could
distinguish
sever
moder
type
collect
conclud
lym
sensit
reliabl
predictor
diseas
type
prognosi
pandem
precis
classif
prognosi
predict
critic
save
insuffici
medic
resourc
stratifi
treatment
improv
surviv
rate
critic
ill
patient
recommend
lym
use
independ
combin
indic
manag
coronaviru
acut
respiratori
infect
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
pandem
spread
worldwid
rapidli
sinc
march
report
individu
diagnos
diseas
caus
death
late
march
rapidli
increas
case
lead
overload
public
healthcar
sourc
run
medic
facil
sever
patient
divid
level
ie
mild
moder
sever
critic
accord
new
coronaviru
pneumonia
diagnosi
program
edit
publish
nation
health
commiss
china
current
experi
reveal
infect
peopl
approx
sever
get
selfheal
small
part
case
care
treat
hospit
howev
mortal
among
sever
especi
critic
patient
quit
high
thu
critic
screen
reliabl
predictor
sever
patient
get
better
outcom
save
medic
sourc
sever
factor
includ
viral
load
lymphocyt
creactiv
protein
crp
procalcitonin
pct
lactic
acid
identifi
warn
indic
prognosi
patient
recent
studi
differ
cohort
patient
howev
still
elus
factor
effect
reliabl
indic
predict
prognosi
earli
stage
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
besid
indic
diseas
classif
also
urgent
need
present
studi
base
clinic
inform
patient
compar
valid
predict
power
sever
report
risk
factor
prognosi
descript
manner
case
taken
gener
hospit
central
theater
command
wuhan
hubei
provinc
peopl
republ
china
studi
approv
ethic
committe
hospit
subject
sign
inform
consent
form
admiss
hospit
total
patient
hospit
januari
march
investig
cure
case
moder
type
moderatecur
cure
case
sever
type
severecur
dead
case
critic
ill
type
critic
illdi
gender
age
inform
patient
present
tabl
patient
confirm
viral
detect
via
oropharyng
swab
use
quantit
rtpcr
rule
infect
respiratori
virus
influenza
viru
influenza
viru
b
coxsacki
viru
respiratori
syncyti
viru
parainfluenza
viru
enteroviru
case
diagnos
classifi
accord
new
coronaviru
pneumonia
diagnosi
program
edit
publish
nation
health
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
commiss
china
clinic
manifest
consist
four
categori
mild
moder
sever
critic
ill
mild
clinic
symptom
mild
pulmonari
inflamm
imag
moder
overwhelm
major
show
symptom
respiratori
infect
fever
cough
sputum
pulmonari
inflamm
imag
symptom
dyspnea
appear
includ
follow
short
breath
rr
blood
oxygen
satur
rest
mmhg
pulmonari
inflamm
progress
significantli
within
hour
classifi
sever
respiratori
failur
shock
organ
failur
requir
intens
care
critic
ill
among
mild
patient
admit
design
hospit
studi
basic
inform
complet
blood
count
serum
biochem
test
inflammatori
indic
viral
load
diseas
outcom
includ
patient
collect
dynam
studi
graphpad
softwar
use
data
statist
map
data
express
analyz
use
twotail
unpair
student
ttest
paramet
data
present
indic
p
indic
p
indic
p
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
investig
mortalityassoci
risk
factor
patient
classifi
cure
die
group
tabl
serum
level
crp
pct
percentag
lymphocyt
lym
lactic
acid
ct
valu
viral
test
measur
dynam
level
crp
peripher
blood
increas
quickli
symptom
onset
increas
end
around
week
later
dead
case
level
crp
survivor
fluctuat
littl
fig
similar
trend
obtain
pct
level
although
began
increas
day
diseas
onset
fig
blood
level
dead
case
increas
rapidli
earli
phase
rose
extraordinari
level
death
fig
contrast
symptom
onset
lym
dead
case
deceas
quickli
sustain
low
level
fig
level
blood
lactic
acid
narrow
time
window
could
distinguish
die
cure
group
fig
day
diseas
onset
predi
patient
obvious
higher
level
viral
load
indic
ct
valu
survivor
fig
taken
togeth
indic
crp
pct
lym
viral
load
could
predict
mortal
risk
differ
degre
lym
crp
sensit
indic
obviou
chang
factor
earli
phase
day
diseas
onset
identifi
cure
die
group
fig
addit
three
indic
long
time
window
distinguish
cure
die
case
could
ensur
accuraci
forecast
fig
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
initi
durat
differ
indic
two
group
key
judg
diseas
type
distinguish
critic
ill
sever
group
initi
day
differ
indic
crp
pct
lym
lactic
acid
ct
respect
fig
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
indic
sever
moder
type
initi
day
differ
indic
crp
lym
ct
respect
contrast
total
differ
pct
level
group
fig
noteworthili
durat
differ
crp
lym
respect
pct
ct
continu
time
window
differenti
fig
result
indic
lym
indic
among
factor
type
sever
moder
patient
given
worldwid
preval
diseas
type
prognost
indic
great
signific
guid
classifi
treatment
prevent
medic
run
save
critic
patient
studi
select
sever
report
risk
factor
prognosi
patient
valid
predict
role
diseas
outcom
classif
first
studi
report
crp
pct
lactic
acid
ct
lym
indic
differ
type
patient
valid
lym
could
permiss
predictor
identifi
critic
ill
sever
moder
case
previou
studi
also
support
conclus
lymphocyt
count
function
close
relat
diseas
statu
patient
insuffici
immun
includ
elder
peopl
immunodefici
alway
present
lower
level
lymphocyt
wors
prognosi
infect
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
addit
rel
stabil
lym
patient
less
overlap
among
group
differ
sever
progress
made
indic
potenti
good
predictor
notabl
describ
serum
level
crp
present
zigzag
curv
whole
cours
diseas
critic
ill
patient
specul
obviou
chang
may
caus
medic
intervent
interestingli
chang
serum
level
two
marker
moder
sever
patient
much
stabl
lower
critic
patient
result
indic
refractori
inflammatori
reaction
identifi
earli
stage
diseas
predict
poor
outcom
patient
featur
brought
forefront
earli
stage
clinic
practic
curv
inflammatori
indic
draw
dynam
like
bodi
temperatur
higher
level
inflammatori
indic
lower
level
lym
lead
anoth
interest
question
whether
storm
inflammatori
cytokin
due
impair
lymphocyt
cell
know
cell
ie
treg
respons
inflammatori
regul
impair
function
treg
cell
may
contribut
uncontrol
inflamm
critic
patient
note
late
stage
dead
case
level
proinflammatori
indic
lym
lactic
acid
acut
increas
fig
phenomenon
indic
absolut
disord
inflamm
immun
metabol
die
patient
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
persist
low
level
ct
valu
viral
test
indic
sustain
high
level
viral
load
critic
ill
patient
howev
note
obviou
differ
durat
viral
shed
sever
nonsever
patient
consist
previou
studi
recent
report
moder
patient
long
durat
viral
shed
day
phenomenon
line
asymptomat
infect
report
popul
present
studi
base
inform
patient
analyz
predict
power
sever
report
indic
diseas
sever
prognosi
descript
manner
found
crp
pct
lym
lactic
acid
viral
load
could
predict
prognosi
guid
classif
patient
differ
degre
crp
lym
effect
three
factor
predict
prognosi
crp
lym
sensit
identifi
type
critic
ill
sever
moder
notabl
among
investig
factor
lym
one
could
distinguish
sever
moder
type
collect
conclud
lym
sensit
reliabl
predictor
diseas
type
prognosi
recommend
lym
use
independ
combin
indic
manag
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
e
dynam
chang
la
level
blood
cure
die
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
